CALCIUM

Informació principal

  • Denominació comercial:
  • CALCIUM SANDOZ 500 mg Ca 30 comprimidos eferv
  • formulario farmacéutico:
  • Comprimidos efervescentes
  • Vía de administración:
  • Oral
  • Utilitza per:
  • Humans
  • Tipo de medicina:
  • medicament al·lopàtic

Documents

Localització

  • Disponible en:
  • CALCIUM SANDOZ 500 mg Ca 30 comprimidos eferv
    Andorra
  • Idioma:
  • català

Altres dades

Estat

  • Font:
  • CedimCat - Centre d'Informació de Medicaments de Catalunya
  • Número d'autorització:
  • 653551
  • última actualització:
  • 08-06-2018

Prospecte

CALCIUM SANDOZ 500 mg Ca 30 comprimidos

eferv

calcio, carbonato+calcio, lactogluconato

Indicacions

Medicament que s'utilitza quan cal una aportaci

extra de calci. El calci

s necessari per enfortir els

ossos.

Consideracions

Prengui els comprimits dissolts en mig got d'aigua.

Prengui aquest medicament despr

s dels menjars.

Segueixi estrictament la pauta indicada pel seu metge pel que fa a dosi i freq

眉猫

ncia d'administraci

Avisi el seu metge si pateix intoler

ncia a alguns sucres.

Avisi el seu metge si pateix o ha patit c

lculs renals o problemes de rony

Aquest medicament modifica l'acci

d'altres f

rmacs, NO prengui altres medicaments sense consultar

abans al seu metge o farmac

utic.

Aquest medicament pot modificar l'efic

cia d'altres f

rmacs, per la qual cosa es recomana separar

l'administraci

2 hores.

Si pren aliments rics en fibra (pa integral, fruites, verdures, etc.), prengui'ls, com a m

nim, 2 hores

abans o despr

s d'haver pres aquest medicament.

Efectes adversos

Si vost

segueix la pauta indicada, no solen apar

ixer efectes adversos.

Posologia

Prengui 1 comprimit despr

s de l'esmorzar, del dinar i del sopar.

Deixi dissoldre el comprimit a un got mig ple d'aigua.

VIA ORAL.

29-8-2018

Modification of the existing maximum residue levels for prohexadione in various oilseeds

Modification of the existing maximum residue levels for prohexadione in various oilseeds

Published on: Mon, 27 Aug 2018 00:00:00 +0200 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant BASF SE submitted a request to the competent national authority in France to modify the existing maximum residue levels (MRL) for the active substance prohexadione in linseeds, poppy seeds, sunflower seeds, rape seeds, mustard seeds and gold of pleasure seeds. The data submitted in support of the request were found to be sufficient to derive MRL proposals for all oilseeds under consid...

Europe - EFSA - European Food Safety Authority Publications

19-12-2008

Consultation responses on the future reimbursement status of dihydropyridine calcium antagonists (C08CA)

Consultation responses on the future reimbursement status of dihydropyridine calcium antagonists (C08CA)

The Danish Medicines Agency's assessment of the future reimbursement status of the dihydropyridine calcium antagonists (C08CA) were submitted for consultation with 11 November 2008 as the consultation deadline.

Danish Medicines Agency

29-10-2008

Reassessment of reimbursement status for medicinal products in ATC group C08CA

Reassessment of reimbursement status for medicinal products in ATC group C08CA

The Danish Medicines Agency has assessed the question of the future reimbursement status for medicinal products in ATC group C08CA (dihydropyridine calcium channel blockers) which are used for the treatment of cardiovascular diseases.

Danish Medicines Agency

8-9-2008

Reassessment of reimbursement status of medicinal products for cardiovascular diseases – additional recommendation from the Reimbursement Committee

Reassessment of reimbursement status of medicinal products for cardiovascular diseases – additional recommendation from the Reimbursement Committee

The Danish Medicines Agency has asked the Reimbursement Committee to reassess the reimbursement status of medicinal products authorised for marketing in Denmark in the ATC groups C02 (antihypertensives), C03 (diuretics), C07 (beta blocking agents), C08 (calcium channel blockers) and C09 (ACE inhibitors, angiotensin II antagonists and renin inhibitors).

Danish Medicines Agency

14-2-2008

Reassessment of reimbursement status for medicinal products for the treatment of cardiovascular diseases

Reassessment of reimbursement status for medicinal products for the treatment of cardiovascular diseases

Following a request from the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status for medicinal products authorised for marketing in Denmark in ATC groups C02 (antihypertensives), C03 (diuretics), C07 (beta blocking agents), C08 (calcium channel blockers) and C09 (ACE inhibitors, angiotensin II antagonists and renin inhibitors).

Danish Medicines Agency

No hay novedades relativo a este producto.